SYMMETREL

This brand name is authorized in Australia, Hong Kong, Japan, Malta, Netherlands, New Zealand, Singapore, South Africa

Active ingredients

The drug SYMMETREL contains one active pharmaceutical ingredient (API):

1 Amantadine UNII M6Q1EO9TD0 - AMANTADINE HYDROCHLORIDE

Amantadine has been shown to be a low affinity antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Overactivity of glutamatergic neurotransmission has been implicated in the generation of parkinsonian symptoms. In addition, amantadine specifically inhibits the replication of influenza A viruses at low concentrations. Read about Amantadine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
Symmetrel Capsules	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N04BB01	Amantadine	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BB Adamantane derivatives
Discover more medicines within N04BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 3016R
Country: HK	Department of Health Drug Office	Identifier(s): 00183
Country: JP	医薬品医療機器総合機構	Identifier(s): 1161001C1089, 1161001F1050, 1161001F2057
Country: MT	Medicines Authority	Identifier(s): AA565/00602, AA565/55801
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 485
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 918
Country: SG	Health Sciences Authority	Identifier(s): 01481P
Country: ZA	Health Products Regulatory Authority	Identifier(s): A/20.2.8/768